Lilly reports weight maintenance with Foundayo and reduced-dose Zepbound
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
May 12, 2026 6:01 PM EDTIn ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all but 0.9 kg of their previously achieved weight loss on average after one year
In ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, participants who switched from Zepbound MTD to Foundayo or reduced the dose of Zepbound to 5 mg, respectively, maintained all but 5.0 kg and 5.6 kg of their previous weight loss on average after one year
Participants in SURMOUNT-MAINTAIN who remained on Zepbound MTD for an additional year maintained all of their prior weight loss on... More
